HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Lowers Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Travere Therapeutics (NASDAQ:TVTX), but lowered the price target from $35 to $32.
August 07, 2023 | 6:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite a lowered price target, HC Wainwright & Co. maintains a 'Buy' rating on Travere Therapeutics, indicating continued confidence in the company's prospects.
The lowered price target may cause some short-term uncertainty among investors, potentially impacting the stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company, which could balance out any negative impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100